New Zealand markets closed

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.88-0.05 (-0.63%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.93
Open7.92
Bid7.51 x 1000
Ask8.60 x 900
Day's range7.88 - 8.07
52-week range7.88 - 35.00
Volume2,273
Avg. volume2,367
Market cap46.398M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-2.75
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Addex to Present at the Investors’ Day hosted by Voxia Communication

    Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors’ Day hosted by Voxia Communication (October 7, 2021). The event will take place at the Beau Rivage Hotel in Geneva. In his presentation, which is scheduled for Thursday, October 7, 2021, at 12:10 CEST, Mr Dyer will provide a corporate upd

  • GlobeNewswire

    Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors

    Geneva, Switzerland, October 4, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Lütjens, Head of Discovery – Biology and Dr Rocher, Head of Discovery – Chemistry, will present today at the 10th International Meeting on Metabotropic Glutamate Receptors (October 1 - 6, 2021). Dr Paparin, Senior Manager – Chemistry, will be participating at the conference as well. In a first

  • GlobeNewswire

    Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

    Type of dystonia characterized by involuntary spasms of the eyelid muscles can lead to substantial visual disturbance or functional blindness Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the initiation of a Phase 2a clinical study with dipraglurant as a potential treatment for bleph